Table 1.
Novel, breast-specific peak 13741 is associated with estrogen-receptor-positive and progesterone-receptor-positive cells and Grade 1 breast cancer
| ER+ | ER- | PR+ | PR- | Grade 1 | Grade 3 | |
|---|---|---|---|---|---|---|
| (n = 146) | (n = 33) | (n = 129) | (n = 50) | (n = 42) | (n = 41) | |
| 13741+ | 122 (83.6%) |
5 (15.2%) |
112 (86.8%) |
15 (30.0%) |
37 (88.1%) |
12 (29.3%) |
| 13741- | 24 (16.4%) |
28 (84.8%) |
17 (13.2%) |
35 (70.0%) |
5 (11.9%) |
29 (70.7%) |
RNA in situ hybridization results for analyses correlating the expression of peak 13741. Numbers of samples are reported. Each test was significant by the Kruskal-Wallis rank sum test. +, staining in >30% of cells; -, staining in <10% of cells; ER, estrogen receptor; PR, progesterone receptor.